Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy

J Acquir Immune Defic Syndr. 2003 Feb 1;32(2):240-2. doi: 10.1097/00126334-200302010-00019.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Alkynes
  • Antiretroviral Therapy, Highly Active
  • Benzoxazines
  • CD4 Lymphocyte Count
  • Cyclopropanes
  • Drug Therapy, Combination
  • Female
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / therapeutic use*
  • HIV-1* / isolation & purification
  • Humans
  • Male
  • Oxazines / pharmacokinetics*
  • Oxazines / therapeutic use
  • Prospective Studies
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Ritonavir / pharmacokinetics*
  • Ritonavir / therapeutic use
  • Saquinavir / pharmacokinetics*
  • Saquinavir / therapeutic use
  • Viral Load

Substances

  • Alkynes
  • Benzoxazines
  • Cyclopropanes
  • HIV Protease Inhibitors
  • Oxazines
  • Reverse Transcriptase Inhibitors
  • efavirenz
  • Saquinavir
  • Ritonavir